A clinical trial to study and compare the effects of Alcaftadine 0.25% eyedrops and Olopatadine 0.1% in patients with Allergic conjunctivitis
- Conditions
- Health Condition 1: H101- Acute atopic conjunctivitisHealth Condition 2: null- ALLERGIC CONJUNCTIVITIS
- Registration Number
- CTRI/2018/10/016170
- Lead Sponsor
- Dr M Karthiga
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)All patients aged > 18 years of both genders clinically diagnosed with allergic conjunctivitis by ophthalmologists.
2)Graded conjunctival redness in at least one region (nasal or temporal) in Eye.
3)Graded ocular itching at any one time point
4)Visual acuity of at least 6/15 in each eye
5)All patients who had an attack history more than 2 years
1)Patients with bacterial, chlamydial, viral and membranous conjunctivitis were excluded
2)Patients with ocular surface disorders like pterygium, dry eye were excluded from the study.
3)Patients who have known hypersensitivity to the drug.
4)History of uveitis, blepharitis, herpes simplex keratitis or herpes zoster keratitis.
5)History of retinal detachment, diabetic retinopathy and progressive retinal disease
6)History of glaucoma, or Intraocular Pressure (IOP) over 25mmHg at the screening visit, or a history of elevated IOP within the past 1 year.
7)Ocular surgery or refractory surgery within 6 months prior to visit 1 or planning to do a surgery during the trial.
8)Use of antibiotics, antivirals, or topical cyclosporine, depot corticosteroids, NSAIDS and other antihistamines or mast cell stabilisers within 1 month of the screening visit.
9)Participants unwilling not to wear contact lenses during the study.
10)Pregnant and lactating women
11)Subjects must not have an ocular itching score >0 or a conjunctival hyperaemia score >1 in either eye in any region (nasal or temporal) at Visit 1.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method